Recombinant Anti-CD28 x Anti-CD30 Bispecific Antibody (Triple Body) is designed to be expressed as two polypeptide chains respectively. The Fd fragment and LC from an anti-CD28 antibody are both extended with the scFv fragment from an anti-CD30 antibody. This BsAb can retarget T cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.
There are currently no customer reviews or questions for Recombinant Human Anti-CD28 x Anti-CD30 Bispecific Antibody (Triple Body) (TRIB-H231). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS